Healthcare
Microalgae are among the first living elements to appear on Earth. They intrinsically carry within them all the functionalities that the human body needs.
From this natural richness, AlgoSource extracts 100% natural bioactive products, very highly concentrated in active ingredients, with clinically proven efficacy, to prevent serious pathologies in the hepatic, cardiovascular and pulmonary spheres or to support drug protocols in oncological applications.
First double-blind vs. placebo clinical study on humans
AlgoSource voluntarily joined an ambitious process aimed at obtaining authorisation from the European Food Safety Authority (EFSA) to make a health-related claim demonstrating, according to the standards of double-blind clinical trials set by the EFSA, the antioxidants properties of Spirulysat®.
From the end of 2017, AlgoSource launched, with Biofortis Mérieux, the first exploratory clinical study, conducted double-blind against placebo, according to the most stringent clinical standards, the results of which confirmed the functional power of Spirulysat®.
Supportive care in oncology
Spirulysat® is the emblematic product of AlgoSource, obtained thanks to a unique and patented process of cold-water extraction, without solvents or chemicals. Performed without any heat treatment, this exclusive process makes it possible to isolate the most powerful active ingredients from spirulina and retain all their original properties.
Spirulysat® is, thus, a pure complex of the molecules of interest in spirulina. Among these, phycocyanins are at the heart of this extract of high added value.
Supportive care in oncology
Spirulysat® is the emblematic product of AlgoSource, obtained thanks to a unique and patented process of cold-water extraction, without solvents or chemicals. Performed without any heat treatment, this exclusive process makes it possible to isolate the most powerful active ingredients from spirulina and retain all their original properties.
Spirulysat® is, thus, a pure complex of the molecules of interest in spirulina. Among these, phycocyanins are at the heart of this extract of high added value.
Preventive care in hepatology
In 2016, AlgoSource entrusted Dr. Khadija Ougerram of CRNH Grand Ouest, researcher within UMR 1280 Physiology of Nutritional Adaptations, with conducting clinical trials aimed at demonstrating the preventive effect of Spirulysat® on non-alcoholic fatty liver disease.
The results obtained, combined with a specific dose effect, confirmed this direct effect on protection of the liver and on prevention of the onset of NASH syndrome.
Preventive cardiovascular care
AlgoSource, with the help of CRNH Grand Ouest, has successfully demonstrated the preventive action of its spirulina extract, Spirulysat®, combined with a significant dose effect, to prevent the formation of atheroma plaques, thereby reducing the risk of this cardiovascular pathology.
This study made it possible to demonstrate a preventive action both on subjects who developed atherosclerosis during their existence as well as on subjects in-utero thanks to ingestion of Spirulysat® by the mother during gestation.
Preventive cardiovascular care
AlgoSource, with the help of CRNH Grand Ouest, has successfully demonstrated the preventive action of its spirulina extract, Spirulysat®, combined with a significant dose effect, to prevent the formation of atheroma plaques, thereby reducing the risk of this cardiovascular pathology.
This study made it possible to demonstrate a preventive action both on subjects who developed atherosclerosis during their existence as well as on subjects in-utero thanks to ingestion of Spirulysat® by the mother during gestation.
Do you have a question?
Contact our team
Do you want to know more about our products, our ingredients from microalgae and our know-how? Contact us!